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Objective: to estimate the prevalence of TaqIA, -141C and rs6280 polymorphisms of the 
ANKK1, DRD2 and DRD3 genes and evaluate their association with the occurrence of metabolic 
syndrome in patients with refractory schizophrenia. Method: cross-sectional study conducted in 
the Extended Western Region of Minas Gerais, with refractory schizophrenic patients using the 
antipsychotic clozapine. Sociodemographic, clinical, anthropometric, biochemical and genetic 
data were collected. Univariate analysis of the data was performed. Results: seventy-two 
patients participated in the study and the occurrence of Metabolic Syndrome was observed 
in 47.2% of them. There was no association between Metabolic Syndrome and the studied 
polymorphisms. There was a statistically significant difference in the low HDL parameter with 
homozygous genotype for the C allele of the -141C polymorphism of the DRD2 gene. Conclusion: 
a high prevalence of MS was evidenced. The -141C polymorphism was associated with low HDL. 
Genetic analysis and identification of metabolic alterations in this group of patients can guide 
drug treatment and provide a better quality of life.
Descriptors: Nursing; Schizophrenia; Genetic Polymorphism; Metabolic X Syndrome; Clozapine; 
Health Profile.
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Introduction
Schizophrenia is considered one of the most serious 
mental disorders nowadays, since its progression affects 
the quality of life of individuals who experience the 
disease and also of their relatives(1). Schizophrenia 
affects more than 21 million people worldwide and is 
considered a major public health problem(1-2). This 
disease is manifested mainly by the presence of 
positive symptoms (change in the thinking process, 
perceptions and affection) and negative symptoms 
(affective-volitional blunting, cognitive losses and 
depressive symptoms)(2).
Approximately 40% of people with schizophrenia 
do not present adequate response to drug treatment 
and persist with symptoms of the disease; they are 
known as refractory schizophrenic people(1-3). Although 
there is no single, globally accepted consensus, 
refractory schizophrenia can be characterized by partial 
response, for at least five years, to three different 
types of antipsychotics (at least two with different 
chemical structures); intolerance to adverse effects; 
and relapses or symptomatic deterioration despite the 
use of appropriate doses of the drugs(3-4). The atypical 
antipsychotic clozapine is considered the gold standard 
for the drug treatment of refractory schizophrenia, 
being associated with clinical improvement and 
decreased hospitalizations(4-5).
In this context, studies have indicated that genetic 
polymorphisms of dopaminergic pathways are related 
to etiopathogenesis and drug response to treatment, as 
well as to a greater susceptibility to clinical alterations. 
Unique or Single Nucleotide Polymorphisms (SNPs) 
consist in a variation of the DNA sequence caused by 
a single nucleotide exchange in the genome sequence. 
Some SNPs alter the amino acid composition of the 
protein and the expression of the receptor, which may 
have an effect on the phenotype of an individual, and 
can also serve as molecular markers of predisposition 
to certain types of diseases. The ability to detect 
polymorphisms at the DNA level is the basis of several 
studies that aim to identify whether this variation causes 
or contributes to a specific phenotype(5-6).
Among the genetic polymorphisms of the most 
studied dopaminergic pathway are the TaqIA, -141C 
and rs6280. These variants are located in the ANKK1, 
DRD2 and DRD3 genes, respectively, which have already 
been addressed by other authors in the literature, 
relating them to the response to antipsychotics and 
metabolic alterations of the individuals making use 
of this drug treatment(4-5). However,  further in-depth 
analyses of how these variants in the DNA sequence can 
influence metabolic alterations in the carriers of these 
polymorphisms are necessary, as this theme is still 
little elucidated(7).
The abovementioned polymorphisms occur in 
genes encoding proteins that contribute to adequate 
signaling of neurotransmitters in the mesocorticolimbic 
pathway or ventral tegmental area. These regions 
play an important role in motivation, guided thinking, 
affective balance and in the reward system, the latter 
being responsible for the feeling of satiety and appetite. 
Psychotropic drugs act primarily in these regions by 
lowering dopamine (DA) levels and therefore reducing 
psychotic symptoms. However, at very low levels, they 
can lead to cognitive impoverishment, depression and 
metabolic alterations(8).
One of the potential consequences of this 
biochemical process is a condition known as Metabolic 
Syndrome (MS)(6-9). MS is characterized by a set of risk 
factors that include abdominal obesity, insulin resistance, 
dyslipidemia and hypertension. The prevalence of MS 
in patients with refractory schizophrenia compared to 
patients with other forms of schizophrenia is higher 
and has more drastic repercussions, reaching 69%(9). 
Although the causal relationship between refractory 
schizophrenia and MS is not fully understood, there is 
evidence of the association between second-generation 
antipsychotics and the development of this syndrome. 
It has been suggested that the presence of negative 
symptoms may increase the risk, which may be 
associated with the sedentary lifestyle and the poor 
quality of life resulting from this condition(10-11).
The genetic analysis of refractory schizophrenic 
patients can become an essential tool in the perspective 
of a care plan using genetic counseling, which can serve 
as a basis to guide the drug treatment and consequently 
provide a better quality of life for these notably more 
severe patients. In view of the above, the present 
study aims to estimate the prevalence of TaqIA, -141C 
and rs6280 polymorphisms of the ANKK1, DRD2 and 
DRD3 genes and to evaluate their association with the 
occurrence of MS in refractory schizophrenic patients.
Method
This is a cross-sectional and analytical study carried 
out in the Extended Western Region of Minas Gerais with 
patients diagnosed with refractory schizophrenia using 
the antipsychotic clozapine. The following inclusion 
criteria were observed: medical diagnosis of refractory 
schizophrenia with use of the atypical antipsychotic 
clozapine, male or female patients older than 18 years 
and with understanding capacity attested by the Mini-
Mental State Examination (MMSE)(12). Pregnant women, 
participants who were not fasting, and those who had 
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any condition that could interfere with the collection 
and measurement of data, such as the presence of 
physical disability that could impair the measurement of 
anthropometric characteristics, were excluded. The need 
for fasting was due to the performance of laboratory 
tests to verify the presence of MS.
The sample calculation was performed using the 
OpenEpi version 3.03a, considering a population of 169 
individuals for an expected proportion of the event of 
50%, a significance level of 5% and a margin of error 
of 10%. A sample of approximately 62 individuals was 
estimated. The final sample consisted of 72 participants.
All individuals who made up the eligible population 
were previously invited to collect data by sending letters 
and making a telephone contact, when they received 
all the necessary guidelines for the research. Data were 
collected from December 2014 to June 2015.
Data were collected at the Psychosocial Care Center 
type III of the municipality-polo of the Great West Region 
in scheduled date and time. The sociodemographic and 
clinical profile of the subjects of this study was surveyed 
through a semi-structured questionnaire prepared by 
the authors, including the following data: gender, age, 
marital status, number of children, family income, 
schooling, and people with whom they reside. The 
following clinical data was surveyed: time of psychiatric 
treatment, previous psychiatric hospitalization, time 
of use of clozapine, number of consultations per year, 
clinical diseases, use of medications, smoking, alcohol 
use, physical activity, perception about the effect of the 
medication and satisfaction with health.
For biochemical and genetic analyses, venous 
blood samples were taken from the cubital vein of the 
forearm after a 12-hour fast. The analysis was done in 
the biochemistry and genetics laboratory of the Federal 
University of São João Del-Rei/Center - Dona Lindu 
West Campus.
In the biochemical evaluation, laboratory tests 
of fasting glycemia (FG), high-density lipoprotein-
cholesterol (HDL-c) and triglycerides (TG) were 
performed. MS was determined according to the criteria 
of the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP-III), which defines the 
MS as the presence of three or more of the following 
risk factors: central obesity (abdominal circumference > 
102cm in men or > 88cm in women); high blood pressure 
(> 130/85mmHg) or on antihypertensive treatment; 
hyperglycemia (fasting blood glucose > 100mg/dL) or 
treatment with hypoglycemic drugs; high triglyceride 
concentration (>150mg/dL) or use of medication to 
reduce it; low HDL-c (< 40mg/dL in men or < 50mg/dL 
in women) or on use of low HDL-c medication(11).
The genetic analysis of peripheral blood samples 
consisted of five steps: the first one was the extraction 
of genomic DNA using the QIAamp Mini Blood Kit 
(Qiagen) according to the manufacturer’s protocol; the 
second step was the amplification ofthe DNA target 
sequences of each of the genes involved in the study 
using Polymerase Chain Reaction (PCR); then, each 
sample of PCR product was subjected to electrophoresis 
to confirm the amplification of the regions of interest; 
for genotyping, the Restriction Fragment Length 
Polymorphism (RFLP) technique was used; and, 
finally, the samples digested in the previous step were 
submitted to an 8% polyacrylamide gel for separation of 
DNA bands, which are expected and identified by their 
respective sizes (number of nitrogenous bases).
Data processing and analysis were performed 
in the Statistical Package for Social Science (SPSS), 
version 20.0. To describe the results, frequency 
distribution tables were used for categorical variables. 
In the analysis of categorical variables, the Pearson 
chi-square of and Fisher’s exact test were used for 
the univariate analysis to evaluate the MS factors 
associated to the polymorphisms. A p-value < 0.20 
was adopted for inclusion of variables in the model. 
The adjusted odds ratio (OR) with a respective 95% 
confidence interval (95% CI) was estimated. The 
goodness of fit of the model was assessed using the 
Hosmer-Lemeshow test.
Hardy-Weinberg equilibrium was analyzed through 
the Pearson chi-square test, comparing the frequencies 
of the genotypes observed with those expected for 
this population. This calculation was performed using 
the Hardy-Weinberg equilibrium calculator software 
including analysis for ascertainment bias (13).
The study was approved by the Research Ethics 
Committee under Protocol nº 1,406,658, in compliance 
with the recommendations of Resolution 466/2012 of 
the National Health Council.
Results
An unintentional finding of the study was that both 
genders were equally represented among the 72 patients 
with refractory schizophrenia in use of clozapine (50%). 
The average age of the participants was approximately 
43 years.
It was verified that the prevalence of MS in the 
studied population was 47.2%, being more frequent 
among females (58.8%), but it was also observed 
that males also had a high incidence rate (41.2%). 
Patients in the age group below 40 years were those 
with the highest prevalence of MS (38.2%). Another 
characteristic identified was the time of treatment with 
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clozapine, in which a prevalence of 65.6% of MS was 
found in those who had used this medication for more 
than 5 years.
Table 1 below shows the percentage distribution 
of the occurrence of each variant, detailed according to 
genotypic and allelic frequencies. The Hardy-Weinberg 
equilibrium, as tested through the chi-square value, 
found at each genotype frequency is shown in the table. 
No deviation was identified. The chi-square table was 
used as reference.
Table 1: Prevalence of the analyzed polymorphisms 
(n = 72). Extended Western Region of Minas Gerais, MG, 
Brazil, 2015
 Percentage N p-value*
TaqIA polymorphism 
Genotypes
Homozygous for the C allele 51.4 37 0.0454
Heterozygous 41.7 30






Homozygous for the Del C 
allele 68.1 49 0.0000
Heterozygous 25.0 18
Homozygous for the Ins C 
allele 6.9 5
Alleles
Del C 80.5 116
Ins C 19.4 28
rs6280 polymorphism 
Genotypes
Homozygous for the C allele 23.6 17 0.0032
Heterozygous 41.7 30




N: observed frequencies * p-value: chi-square test
Table 2 shows the association of the studied 
polymorphisms with MS. Regarding genotypic and allelic 
analyses, there was no statistically significant difference 
with MS (p > 0.05).
There was no association considering the three 
components of MS, high blood pressure, central 
obesity and hypertriglyceridemia according to the 
polymorphisms of interest in this study. Low HDL showed 
a significant association with homozygous genotype for 
the Ins C allele of the -141C polymorphism of the DRD2 
gene (p < 0.05), as described in Table 3.
Table 2: Analysis of association of polymorphisms in 
patients with and without metabolic syndrome* (n = 72). 
Extended Western Region of Minas Gerais, MG, Brazil, 2015
Polymorphism Without MS* With MS* p†
N % N %
TaqIA genotypes 
Homozygous for the C allele 21 55.3 16 47.1 0.708
Heterozygous 15 39.5 15 44.1
Homozygous for the T allele 2 5.3 3 8.8
TaqIA alleles 
C 36 67.9 31 63.3 0.620
T 17 32.1 18 36.7
-141C genotypes 
Homozygous for the Del C 
allele 25 65.8 24 70.6 0.184
Heterozygous 12 31.6 6 17.6
Homozygous for the Ins C 
allele 1 2.6 4 11.8
-141C alleles 
Del C 37 74.0 30 75.0 0.914
Ins C 13 26.0 10 25.0
rs6280 genotypes 
Homozygous for the T allele 16 42.1 9 26.5 0.311
Heterozygous 13 34.2 17 50.0
Homozygous for the C allele 9 23.7 8 23.5
rs6280 alleles 
C 45 40.8 25 41.7 0.551
T 29 59.2 35 58.3
*Metabolic Syndrome †χ² Test; level of significance: p < 0.05.
Table 3: Analysis of association of polymorphisms 
according to the metabolic syndrome component - Low 
HDL* (n = 72). Extended Western Region of Minas Gerais, 
MG, Brazil, 2015
Polymorphism Without low HDL*
With 
low HDL* p†
N % N %
TaqIA genotypes
Homozygous for the C 
allele 30 52.6 7 46.7 0.901
Heterozygous 23 40.4 7 46.7
Homozygous for the T 
allele 4 7.0 1 6.7
TaqIA alleles
W 83 72.8 21 70.0 0.819
T 31 27.2 9 30.0
-141C genotypes 
Homozygous for the Del 
C allele 38 66.7 11 73.3 0.032
Heterozygous 17 29.8 1 6.7
Homozygous for the Ins 
C allele 2 3.5 3 20.0
-141C alleles 
Del C 93 81.6 23 76.7 0.545
Ins C 21 18.4 7 23.3
rs6280 genotypes 
Homozygous for the T 
allele 20 35.1 5 33.3 0.952
Heterozygous 24 42.1 6 40.0
Homozygous for the C 
allele 13 22.8 4 26.7
rs6280 alleles 
W 50 43.9 14 46.7 0.874
T 64 56.1 16 53.3
*High-Density Lipoprotein †χ² Test; level of significance: p < 0.05.
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As for hyperglycemia, the only polymorphism that 
presented a statistically significant association was the 
rs6280 of the DRD3 gene, in which the homozygous 
genotype for the T allele had a higher prevalence and 
was associated with non-hyperglycemia, as shown in 
the table below (Table 4).
Table 4: Analysis of association of polymorphisms 
according to the metabolic syndrome component - 
Hyperglycemia (n = 72). Extended Wester Region of 





N % N %
TaqIA genotypes
Homozygous for C 
allele 15 62.5 22 45.8 0.084
Heterozygous 6 25.0 24 50.0
Homozygous for T allele 3 12.5 2 4.2
TaqIA alleles
W 36 75.0 68 70.8 0.554
T 12 25.0 28 29.2
-141C genotypes 
Homozygous for C allele 15 62.5 34 70.8 0.098
Heterozygous 9 37.5 9 18.8
Homozygous for Ins C 
allele 0 0 5 10.4
-141C alleles 
Del C 39 81.3 77 80.2 0.776
Ins C 9 18.8 19 19.8
rs6280 genotypes 
Homozygous for T allele 13 54.2 12 25.0 0.040
Heterozygous 6 25.0 24 50.0
Homozygous for C 
allele 5 20.8 12 25.0
rs6280 alleles 
W 16 33.3 48 50.0 0.021
T 32 66.7 48 50.0
*χ² Test; significance level: p <0.05.
The result of the analysis of the factor associated 
with the -141C variant of the DRD2 and rs6280 genes, 
component of the syndrome, low HDL, is shown in Table 
5. The homozygous genotype for the Ins C allele of the 
-141C polymorphism (OR: 19.8) was associated with 
low HDL, that is, in this study, it was evidenced that 
a patient diagnosed with refractory schizophrenia who 
presented the -141C variant of the DRD2 gene and 
had the homozygous genotype for the Ins C allele was 
almost 20-fold more likely to present a low HDL level 
when compared to the heterozygous genotype.
Table 5: Odds Ratio Calculation* (OR) with respective 
95%Confidence Interval (95% CI). Extended Western 
Region of Minas Gerais, MG, Brazil, 2015
OR* CI 95%† for OR
Low limit Upper limit 
-141C polymorphism Low HDL
Genotypes
Heterozygous 1.00 - -
Homozygous for the Ins C allele 19.8 1.51 701.1
* Odds Ratio †95% CI - 95% Confidence Interval.
Discussion
This investigation brings as one result the 
non-association of the TaqIA, -141C and rs6280 
polymorphisms of the dopaminergic system with MS. 
However, it is a very relevant investigation because 
it showed the components that can lead to MS. In 
addition, a better elucidation of these factors is 
important to avoid other disastrous complications in 
the health of these patients(14).
Metabolic disturbances are more prevalent in 
schizophrenic patients than in the general population 
and this may translate into an increased risk of chronic 
degenerative diseases and even mortality in this 
group(14). According to Papanastasiou (2013), women 
tend to have increased rates of MS compared to men, 
a datum corroborated in the present study. However, 
that data must be carefully interpreted; men are likely 
to be at increased risk of developing cardiovascular 
disease as the possible result of a combination of 
unhealthy lifestyles and lack of health care when 
compared to women(15-16).
The present study revealed a statistically 
significant difference in the genotypic distribution 
of the SNP -141C Ins/Del of the DRD2 gene, with 
association of the homozygous Ins C genotype when 
analyzed with the low HDL levels. Some studies that 
have investigated the association of this polymorphism 
with schizophrenia found an increased frequency 
of this allele (Ins) in this group of patients(17-18). 
A study conducted in 2010 found that significant 
weight gain was confirmed after 6 weeks of treatment 
with risperidone or olanzapine in the population of 
patients with the -141C Del allele. (19). In the present 
investigation, the Del C allele was also observed to 
have the highest frequency.
An investigation that sought to characterize the 
metabolic profile of patients who presented the first 
episode of schizophrenic outbreak reported a higher 
prevalence of low HDL in this group than the general 
population, but there was no association with the 
genetic profile of this population(20). Low HDL levels 
predict increased cardiovascular risk, while high HDL 
levels are associated with a drop of up to 40% in 
cardiovascular risk compared to low HDL alone; that is 
to say, when HDL levels are below the recommended 
levels, there is risk of complications, especially of 
cardiac nature(21-22).
There are studies that provide evidence of 
the association of altered glycemic levels with 
schizophrenia, but no association with the rs6280 
polymorphism of the DRD3 gene has been found 
in the literature(8-23). A study that analyzed the 
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use of conventional and atypical antipsychotics in 
schizophrenic patients and correlated this factor with 
MS and its components showed that clozapine was 
the second most potent drug in the induction of MS. 
It also demonstrated that this drug was related with 
weight gain in patients after 16 weeks of continuous 
treatment, together with a significant increase in 
glycemic and lipid parameters(24).
The change in glycemic levels in this particular 
group of patients may have even more harmful 
repercussions because the disease may induce 
metabolic alterations and some drug treatments 
may potentiate this risk. It is therefore necessary to 
monitor glycemic levels in all patients diagnosed with 
refractory schizophrenia in order to reduce morbidity 
and mortality risks. The present study found the 
association of the genotype of this variant rs6280 
to absence of hyperglycemia, and this suggests that 
the presence of this variant, especially in those who 
present homozygosis for the T allele, is a protective 
factor against hyperglycemia.
The monitoring of this metabolic alteration is 
fundamental for the evaluation of cardiovascular risk. 
The imbalance of this marker is an indicator of risk for 
chronic-degenerative diseases and increased mortality. 
Routine follow-up on a regular basis and education 
on healthy lifestyle are necessary to minimize the 
risks of complications(2-15). The hypotheses raised in 
this study suggest that the health care for refractory 
schizophrenic patients using clozapine must be 
comprehensive, and the planning of strategies aimed 
at minimizing the risk of metabolic alterations should 
be one of the main goals of the individual therapeutic 
plan for these patients(2-14).
The findings of this study indicated relevant issues 
when highlighted the vulnerability to which refractory 
schizophrenic patients are exposed. Metabolic 
changes increase the risk for the development of 
cardiovascular diseases and other health implications, 
which directly interfere with the quality of life of these 
patients. Therefore, it is essential to develop planned 
actions and periodic monitoring of plasma levels of 
biochemical markers that may lead to MS in order to 
prevent metabolic alterations.
In this sense, it is important that professionals 
directly involved in the care of these patients know 
their different metabolic profiles and the possible 
adverse effects to which they are exposed, so as to 
conduct the appropriate treatment for each of them. 
Awareness of the possibility of these effects must 
also be raised among patients, allied to promotion of 
healthy habits, especially regarding a healthy diet and 
the practice of physical activity.
The limitations of this study are related to its 
external validity, considering that the sample was 
not probabilistic and caution is necessary regarding 
the generalization of the results. The research 
design allowed estimating the prevalence of the 
polymorphisms as well as the associated factors, and 
it is not possible, therefore, to make cause-effect 
inferences. In addition, we suggest the development of 
longitudinal researches to improve the understanding 
of aspects pertinent to the development of MS, 
establishing associations with the polymorphisms 
of interest. However, the chosen design provided 
satisfactory responses to the guiding questions and 
objectives of the study.
Conclusion
The results of this study indicated that 
the prevalence of MS in people with refractory 
schizophrenia using clozapine is high, but there was 
no association with the polymorphisms of interest. The 
ancestral genotype appeared to be a protective factor 
against hyperglycemia in this sample. Therefore, 
these findings point to the need to carry out further 
studies involving genetic analyses and MS in patients 
with refractory schizophrenia in order to guide the 
drug treatment and promote a better quality of life of 
this clientele.
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